Literature DB >> 17445158

Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors.

E W Petersdorf1, T Gooley, M Malkki, M Horowitz.   

Abstract

The application of unrelated donor hematopoietic cell transplantation can be expanded with the use of mismatched donors if human leukocyte antigen (HLA) disparity does not lead to increased morbidity and mortality. The rules that govern permissibility of HLA mismatches are not well defined. The International Histocompatibility Working Group in hematopoietic cell transplantation measured the risks associated with locus-specific disparity in 4796 patients transplanted for low, intermediate, or high-risk hematologic diseases. The permissibility of a given HLA mismatch is in part defined by the locus and by disease risk.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17445158     DOI： 10.1111/j.1399-0039.2006.759_2.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN： 0001-2815


  18 in total

1.  A perspective on the selection of unrelated donors and cord blood units for transplantation.

Authors:  Stephen R Spellman; Mary Eapen; Brent R Logan; Carlheinz Mueller; Pablo Rubinstein; Michelle I Setterholm; Ann E Woolfrey; Mary M Horowitz; Dennis L Confer; Carolyn K Hurley
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

Review 2.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

3.  The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis.

Authors:  Francesca Lorentino; Myriam Labopin; Katharina Fleischhauer; Fabio Ciceri; Carlheinz R Mueller; Annalisa Ruggeri; Avichai Shimoni; Martin Bornhäuser; Andrea Bacigalupo; Zafer Gülbas; Yener Koc; William Arcese; Benedetto Bruno; Johanna Tischer; Didier Blaise; Giuseppe Messina; Dietrich W Beelen; Arnon Nagler; Mohamad Mohty
Journal:  Blood Adv       Date:  2017-04-21

4.  Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.

Authors:  Francesca Lorentino; Myriam Labopin; Fabio Ciceri; Luca Vago; Katharina Fleischhauer; Boris Afanasyev; Nicolaus Kröger; Jan J Cornelissen; Montserrat Lovira; Ellen Meijer; Antonin Vitek; Ahmet Elmaagacli; Didier Blaise; Annalisa Ruggeri; Christian Chabannon; Arnon Nagler; Mohamad Mohty
Journal:  Leukemia       Date:  2020-05-14       Impact factor: 11.528

5.  HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.

Authors:  Michael R Verneris; Stephanie J Lee; Kwang Woo Ahn; Hai-Lin Wang; Minoo Battiwalla; Yoshihiro Inamoto; Marcelo A Fernandez-Vina; James Gajewski; Joseph Pidala; Reinhold Munker; Mahmoud Aljurf; Wael Saber; Stephen Spellman; John Koreth
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-06       Impact factor: 5.742

Review 6.  Current and future approaches for control of graft-versus-host disease.

Authors:  John Koreth; Joseph H Antin
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

7.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Authors:  H Joachim Deeg; Bart L Scott; Min Fang; Howard M Shulman; Boglarka Gyurkocza; David Myerson; John M Pagel; Uwe Platzbecker; Aravind Ramakrishnan; Jerald P Radich; Brenda M Sandmaier; Mohamed Sorror; Derek L Stirewalt; Wendy A Wilson; Rainer Storb; Frederick R Appelbaum; Ted Gooley
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

8.  Proinflammatory cytokines as potential risk factors of acute graft-versus-host disease and infectious complications after allogeneic hematopoietic stem cell transplantation.

Authors:  Malwina Rybicka-Ramos; Miroslaw Markiewicz; Aleksandra Suszka-Switek; Ryszard Wiaderkiewicz; Sylwia Mizia; Monika Dzierzak-Mietla; Krzysztof Bialas
Journal:  Am J Blood Res       Date:  2021-04-15

9.  Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

Authors:  John Koreth; Kristen E Stevenson; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Philippe Armand; Vincent T Ho; Corey Cutler; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Edwin P Alyea
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

10.  HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors.

Authors:  Rene Duquesnoy; Stephen Spellman; Michael Haagenson; Tao Wang; Mary M Horowitz; Machteld Oudshoorn
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.